受强制性开放获取政策约束的文章 - Sanlorenzo Martina MD, PhD了解详情
无法在其他位置公开访问的文章：1 篇
Role of interferon in melanoma: old hopes and new perspectives
M Sanlorenzo, I Vujic, F Carnevale-Schianca, P Quaglino, L Gammaitoni, ...
Expert Opinion on Biological Therapy 17 (4), 475-483, 2017
强制性开放获取政策： Government of Italy
可在其他位置公开访问的文章：28 篇
Pembrolizumab cutaneous adverse events and their association with disease progression
M Sanlorenzo, I Vujic, A Daud, A Algazi, M Gubens, SA Luna, K Lin, ...
JAMA dermatology 151 (11), 1206-1212, 2015
强制性开放获取政策： US National Institutes of Health
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium
P Quaglino, M Maule, HM Prince, P Porcu, S Horwitz, M Duvic, R Talpur, ...
Annals of Oncology 28 (10), 2517-2525, 2017
强制性开放获取政策： Cancer Research UK
The risk of melanoma in airline pilots and cabin crew: a meta-analysis
M Sanlorenzo, MR Wehner, E Linos, J Kornak, W Kainz, C Posch, I Vujic, ...
JAMA dermatology 151 (1), 51-58, 2015
强制性开放获取政策： US National Institutes of Health
Melanoma immunotherapy
M Sanlorenzo, I Vujic, C Posch, A Dajee, A Yen, S Kim, M Ashworth, ...
Cancer biology & therapy 15 (6), 665-674, 2014
强制性开放获取政策： US National Institutes of Health
Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma
M Sanlorenzo, A Choudhry, I Vujic, C Posch, K Chong, K Johnston, ...
Journal of the American Academy of Dermatology 71 (6), 1102-1109. e1, 2014
强制性开放获取政策： US National Institutes of Health
DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics
A Latorre, C Posch, Y Garcimartín, A Celli, M Sanlorenzo, I Vujic, J Ma, ...
Nanoscale 6 (13), 7436-7442, 2014
强制性开放获取政策： Government of Spain
Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer
I Vujic, M Sanlorenzo, C Posch, R Esteve-Puig, AJ Yen, A Kwong, ...
Oncotarget 6 (2), 969, 2014
强制性开放获取政策： US National Institutes of Health
Combined inhibition of MEK and Plk1 has synergistic antitumor activity in NRAS mutant melanoma
C Posch, BD Cholewa, I Vujic, M Sanlorenzo, J Ma, ST Kim, S Kleffel, ...
Journal of Investigative Dermatology 135 (10), 2475-2483, 2015
强制性开放获取政策： US National Institutes of Health, US Department of Veterans Affairs
The risk of melanoma in pilots and cabin crew: UV measurements in flying airplanes
M Sanlorenzo, I Vujic, C Posch, JE Cleaver, P Quaglino, S Ortiz-Urda
JAMA dermatology 151 (4), 450-452, 2015
强制性开放获取政策： US National Institutes of Health
Cytokine-induced killer cells kill chemo-surviving melanoma cancer stem cells
L Gammaitoni, L Giraudo, M Macagno, V Leuci, G Mesiano, R Rotolo, ...
Clinical Cancer Research 23 (9), 2277-2288, 2017
强制性开放获取政策： Government of Italy
Phosphoproteomic analyses of NRAS (G12) and NRAS (Q61) mutant melanocytes reveal increased CK2α kinase levels in NRAS (Q61) mutant cells
C Posch, M Sanlorenzo, I Vujic, JA Oses-Prieto, BD Cholewa, ST Kim, ...
Journal of Investigative Dermatology 136 (10), 2041-2048, 2016
强制性开放获取政策： US National Institutes of Health
BRAF and MEK inhibitors increase PD-1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti–PD-1 antibody
M Sanlorenzo, I Vujic, A Floris, M Novelli, L Gammaitoni, L Giraudo, ...
Clinical Cancer Research 24 (14), 3377-3385, 2018
强制性开放获取政策： Government of Italy
Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells
I Vujic, M Sanlorenzo, R Esteve-Puig, M Vujic, A Kwong, A Tsumura, ...
Oncotarget 7 (6), 7297, 2016
强制性开放获取政策： US National Institutes of Health
Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox
A Goldenberg, I Vujic, M Sanlorenzo, S Ortiz-Urda
Clinical, cosmetic and investigational dermatology, 423-429, 2015
强制性开放获取政策： US National Institutes of Health
Mutant NRASQ61 shares signaling similarities across various cancer types–potential implications for future therapies
I Vujic, C Posch, M Sanlorenzo, AJ Yen, A Tsumura, A Kwong, ...
Oncotarget 5 (17), 7936, 2014
强制性开放获取政策： US National Institutes of Health
The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanoma
M Sanlorenzo, I Vujic, R Esteve-Puig, K Lai, M Vujic, K Lin, C Posch, ...
Scientific reports 8 (1), 10902, 2018
强制性开放获取政策： US National Institutes of Health, Howard Hughes Medical Institute
Phenotypical characterization of circulating cell subsets in pyoderma gangrenosum patients: the experience of the Italian immuno‐pathology group
P Quaglino, P Fava, M Caproni, E Antiga, C De Simone, M Papini, ...
Journal of the European Academy of Dermatology and Venereology 30 (4), 655-658, 2016
强制性开放获取政策： Government of Italy
Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles
C Posch, A Latorre, MB Crosby, A Celli, A Latorre, I Vujic, M Sanlorenzo, ...
Biomedical microdevices 17, 1-9, 2015
强制性开放获取政策： US National Institutes of Health
Searching for the chokehold of NRAS mutant melanoma
C Posch, I Vujic, B Monshi, M Sanlorenzo, F Weihsengruber, ...
Journal of Investigative Dermatology 136 (7), 1330-1336, 2016
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定